Loading...
Living Modified Organism (LMO)
  |  
Decisions on the LMO Risk Assessments  
last updated: 14 Sep 2026
Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
AviPro® Megan® Vac 1 vaccine
EN
AVIPRO MEGAN VAC 1
No
AviPro® Megan® Vac 1 is a live attenuated veterinary vaccine intended to reduce colonization by Salmonella in chickens. The vaccine consists of a genetically modified strain of Salmonella enterica subsp. enterica serovar Typhimurium in which the cyaA and crp genes have been disrupted, resulting in attenuation of the bacterium while retaining its ability to induce a protective immune response. The vaccine helps reduce colonization by Salmonella Typhimurium, Salmonella Enteritidis and Salmonella Heidelberg in growing chickens.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
EN
Characteristics of the modification process
P22HTint
EN
  • Agrobacterium-mediated DNA transfer
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
  • BCH-GENE-SCBD-301085-1 Adenylate cyclase | Salmonella typhimurium (SALTM)
    Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-GENE-SCBD-301086-1 cAMP-activated global transcriptional regulator CRP | Salmonella typhimurium (SALTM)
    Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
Information on the modified genetic elements

AviPro® Megan® Vac 1 is derived from Salmonella enterica subsp. enterica serovar Typhimurium strain UK-1 and is attenuated by mutations affecting the cyaA and crp genes. These mutations were generated using Tn10-mediated mutagenesis and bacteriophage P22 HT int-mediated transduction. The combined disruption of cyaA and crp interferes with cAMP-dependent regulation and contributes to attenuation of S. Typhimurium while retaining sufficient viability and immunogenicity for use as a live vaccine.

(1) cyaA gene

The cyaA gene encodes adenylate cyclase (CyaA), the enzyme responsible for the synthesis of cyclic adenosine monophosphate (cAMP). cAMP participates, together with the cAMP receptor protein (CRP), in the global regulation of numerous metabolic and physiological processes in Salmonella. During development of the attenuated strain, a Tn10-associated mutation affecting cyaA was transferred by generalized transduction using bacteriophage P22 HT int.  The resulting modification disrupts normal cyaA function and is commonly described as a Δcya or ΔcyaA mutation. More recent whole-genome sequence analysis of the commercial AviPro® Megan® Vac 1 strain confirmed disruption of cyaA, corresponding to locus STM3939 in the S. Typhimurium LT2 reference genome, and identified residual IS10-like sequence at the disrupted locus.

(2) crp gene

The crp gene encodes the cyclic AMP receptor protein (CRP), a global transcriptional regulator that interacts with cAMP and controls expression of numerous genes involved in bacterial metabolism and other cellular functions. A Tn10-associated mutation affecting crp was similarly introduced using P22 HT int-mediated generalized transduction, followed by selection of tetracycline-sensitive, fusaric-acid-resistant derivatives. The resulting modification disrupts normal crp function and is commonly described as a Δcrp mutation. Whole-genome sequence analysis of the commercial AviPro® Megan® Vac 1 strain confirmed disruption of crp, corresponding to locus STM3466 in the S. Typhimurium LT2 reference genome, and identified residual IS10-like sequence at the disrupted locus.

Note:
Bacteriophage P22 HT int was used as a generalized transducing phage during construction of the attenuated strain. It served as a vehicle for transferring Tn10-associated cyaA and crp mutations into the S. Typhimurium recipient background and was not intended to remain as an intact genetic element in the final vaccine strain.
Tn10 was used as part of the mutagenesis and selection procedure. The transposon contains IS10 elements associated with genes conferring tetracycline resistance. Following transduction and selection, tetracycline-sensitive derivatives were obtained using fusaric-acid selection. Therefore, the tetracycline-resistance phenotype associated with Tn10 was not retained in the final attenuated strain.
Whole-genome sequencing of the commercial AviPro® Megan® Vac 1 strain subsequently identified IS10-like sequences at both the disrupted cyaA and crp loci. The residual transposon-derived sequences were determined to be at least 1,329 bp in length; however, their exact length and complete organization could not be resolved using the available short-read sequencing data. Genes conferring tetracycline resistance were not detected.
EN
LMO characteristics
EN
  • Vaccine
Detection method(s)
EN
Additional Information
EN
Loading...